Morphogen-IX is a drug discovery company that develops bone morphogenetic proteins for the treatment of pulmonary arterial hypertension. Morphogen-IX was founded in 2015. Morphogen-IX's headquarters is located in Cambridge, England, GB CB22 3AT.
There have been no acquisitions found related to Morphogen-IX
Recent investment data cannot be found related to Morphogen-IX